David Mushatt, MD
Infectious Disease · New Orleans, LANPI 1235222324
Payments from drug & device makers
Across 28 payments — averaging $19.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cormedix Inc.$59
- Viiv Healthcare Company$58
- Merck$54
- Melinta Therapeutics, LLC$49
- Aurinia Pharma U.S., Inc.$45
- Paratek Pharmaceuticals, Inc.$44
- plus $241 from 9 others
What the payments were for
- Food & beverage$53597%
- Education$163%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cormedix Inc. | 3 | $59 |
| Viiv Healthcare Company | 3 | $58 |
| Merck | 3 | $54 |
| Melinta Therapeutics, LLC | 2 | $49 |
| Aurinia Pharma U.S., Inc. | 2 | $45 |
| Paratek Pharmaceuticals, Inc. | 3 | $44 |
| AstraZeneca | 2 | $41 |
| EMD Serono, Inc. | 2 | $39 |
| AbbVie | 2 | $39 |
| ANI Pharmaceuticals, Inc. | 1 | $32 |
| La Jolla Pharmaceutical Company | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Insmed, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $12 |
How this compares
$551 in reported general payments places this provider in the 40th percentile of 105 infectious disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DescovyEmtricitabine/Tenofov Alafenam | 112 | $257,233 |
| IsentressRaltegravir Potassium | 98 | $190,338 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 36 | $154,250 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 37 | $149,007 |
| TivicayDolutegravir Sodium | 37 | $109,866 |
| Daptomycin | 69 | $88,418 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 22 | $85,387 |
| Maraviroc | 24 | $57,648 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 12 | $53,090 |
| JulucaDolutegravir/Rilpivirine | 14 | $46,752 |
| Etravirine | 37 | $44,365 |
| Darunavir | 41 | $37,623 |
| ErtapenemErtapenem Sodium | 45 | $26,649 |
| VemlidyTenofovir Alafenamide | 11 | $18,458 |
| Meropenem | 38 | $15,616 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckIsentress | $54 | $190,33898 claims |
| Viiv Healthcare CompanyTivicay, Juluca | $58 | $156,61851 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 105 infectious disease providers in Louisiana.
Other infectious disease in New Orleans
- Julia Garcia-DiazNew Orleans$9.9M
- Rebecca LillisNew Orleans$2.7M
- Jonathan HandNew Orleans$1.7M
- Stephanie TaylorNew Orleans$1.6M
- George PankeyNew Orleans$851K
- Meredith ClementNew Orleans$829K
- Joseph DalovisioNew Orleans$634K
- Yussef BennaniNew Orleans$173K
- Stacy GreeneNew Orleans$155K
- John SchieffelinNew Orleans$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.